BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31407636)

  • 1. Characterization of Activating Mutations of the
    Borrelli N; Panebianco F; Condello V; Barletta JA; Kaya C; Yip L; Nikiforova MN; Nikiforov YE
    Thyroid; 2019 Sep; 29(9):1279-1285. PubMed ID: 31407636
    [No Abstract]   [Full Text] [Related]  

  • 2. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
    Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
    World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
    Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
    Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
    Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Follicular Thyroid Neoplasms With Papillary-like Nuclear Features Are Genetically and Biologically Similar to Adenomatous Nodules and Distinct From Papillary Thyroid Carcinomas With Extensive Follicular Growth.
    Johnson DN; Furtado LV; Long BC; Zhen CJ; Wurst M; Mujacic I; Kadri S; Segal JP; Antic T; Cipriani NA
    Arch Pathol Lab Med; 2018 Jul; 142(7):838-850. PubMed ID: 29582677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
    Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
    Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA
    Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors.
    Minna E; Devecchi A; Pistore F; Paolini B; Mauro G; Penso DA; Pagliardini S; Busico A; Pruneri G; De Cecco L; Borrello MG; Sensi M; Greco A
    Front Endocrinol (Lausanne); 2023; 14():1267499. PubMed ID: 37867524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
    J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.
    Chen H; Luthra R; Routbort MJ; Patel KP; Cabanillas ME; Broaddus RR; Williams MD
    Mol Cancer Ther; 2018 Jul; 17(7):1575-1584. PubMed ID: 29695638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.